Articles by tag: anti-vegf

FDA approved the first ophthalmic bevacizumab LYTENAVA for the treatment of wet AMD

FDA accepted Outlook Therapeutics' appeal and will approve LYTENAVA — a standardized bevacizumab for neovascular AMD. Analysis of consequences for the anti-VEGF market, pricing, and patients. Read more.

FDA may approve ophthalmic bevacizumab Lytenava

Analysis of the regulatory paradox: why the FDA rejected it three times, while Europe approved it. Learn how the Lytenava decision will change the $16 billion AMD market.